Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) vs enVVeno Medical Corporation (NVNO)

A side-by-side comparison of Cuprina Holdings (Cayman) Limited Class A Ordinary Shares and enVVeno Medical Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares logo
CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
$6M
$2.17HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
enVVeno Medical Corporation logo
NVNO
enVVeno Medical Corporation
$6M
$8.20HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — CUPR vs NVNO

growth of $100 · dividends reinvested · last 1y
CUPR -93.2% (-93.2%/yr)NVNO -89.4% (-89.4%/yr)NVNO compounded faster over this window
050100150200250Start $1002026$7$11
CUPR NVNO

CUPR vs NVNO: by the numbers

  • •CUPR is the larger company ($6M vs $6M market cap).
  • •Both run net losses; NVNO's is the smaller (0.00% vs -9366.75% net margin).

Metrics side by side

Valuation

MetricCUPRNVNO
P/B ratio1.480.28

Profitability

MetricCUPRNVNO
Gross margin-1.29%0.00%
Operating margin-9154.62%0.00%
Net margin-9366.75%0.00%
ROE-92.44%-76.07%
ROIC-84.15%-80.65%

Growth (annualized)

MetricCUPRNVNO
Total return CAGR (5Y)N/A-52.99%

Go deeper

Full CUPR analysisFull NVNO analysisInteractive comparison tool

Dig into the metrics

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares ROEenVVeno Medical ROECuprina Holdings (Cayman) Limited Class A Ordinary Shares operating marginenVVeno Medical operating marginCuprina Holdings (Cayman) Limited Class A Ordinary Shares revenue growthenVVeno Medical revenue growthCuprina Holdings (Cayman) Limited Class A Ordinary Shares free cash flowenVVeno Medical free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.